Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alvotech’s Ustekinumab Passes Safety And Efficacy Milestone

Company Reports Fresh Data For AVT04 Biosimilar Rival To Stelara

24 May 2022

• By Dave Wallace

Clinical Trial Icon — Alvotech has reported further clinical trial results for its ustekinumab candidate • Source: Shutterstock

Related Content

Alvotech Reveals Positive Data For Stelara Rival

16 May 2022

Teva And Alvotech Strike US Biosimilars Pact

05 Aug 2020

Hikma’s US Biosimilars Ambitions Begin With $150m Ustekinumab Deal

27 Aug 2021

Alvotech Could Upend Expectations For US Humira Biosimilars

03 Feb 2022

Alvotech Reveals Action Date For Interchangeable Adalimumab BLA

07 Mar 2022

Amgen’s Stelara Biosimilar Produces Positive Phase III Results

19 Apr 2022

BioFactura’s Ustekinumab Biosimilar To Be Trialed As ‘Robotic’ Pill

14 Sep 2021

Alvotech Eyes $450m Funding And Public Listing With SPAC Merger

08 Dec 2021

Alvotech And Stada Make Biosimilars Pact

07 Nov 2019

Related Companies

Alvotech

Additional Topics

Biosimilars Clinical Trials Strategy BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.